Replies to post #249845 on Biotech Values

[DewDiligence]

BIVI—(+113%)—reports phase-2 Parkinson’s data:

https://www.globenewswire.com/news-release/2024/03/01/2838786/0/en/BioVie-s-NE3107-Demonstrates-Potential-Improvements-in-Motor-and-Non-motor-Symptoms-for-Parkinson-s-Disease-Patients-and-May-Be-Realigning-Physiological-Processes-for-Alzheimer-s-P.html

Even after today’s jump, the share price is down 50% from 11/28/23, the day before BIVI issued a PR on “data integrity” problems in its phase-3 AD trial (#msg-173317222).